This real-world comparative effectiveness study evaluates methylene blue and high-dose hydroxocobalamin as adjunctive vasodilator therapies in septic shock patients when standard treatments fail. The research uses a large multicenter electronic health record network to compare hemodynamic outcomes between these two compounds. For practitioners using peptide and compound-based protocols, this data provides evidence on an emerging supportive therapy class that may complement standard sepsis management.
For your business
Real-world EHR data comparing MB vs hydroxocobalamin in septic shock supports MB as a viable adjunctive option when standard vasopressors fall short.